Earnings
|
Adjusted gross margin… Adjusted gross margin before fair value adjustments on cannabis net revenue was 54% in Q3 2022 versus 53% in the prior quarter and 44% in Q3 2021. The increase in adjusted gross margin compared to the prior year period is due to increased sales in our international medical markets which command significantly higher average net selling prices and margins. ShowHide Related Items >><< - 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 02/10/22
- Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023
- 02/03/22
- Aurora Cannabis' Reliva launches new product line, KG7
- 12/14/21
- Aurora Cannabis and 22nd Century sign license agreement with Cronos Group
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 02/11/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
- 02/03/22 CIBC
- Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
- 11/11/21 Canaccord
- Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 11/15/21
- Republicans introduce cannabis legalization bill, Insider says
- 05/12/22
- Rising High: Exclusive talk with cannabis REIT NewLake Capital
- 05/05/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 04/28/22
- Here's What You Missed in Cannabis This Week
- 04/21/22
- Rising High: Exclusive talk with psychedelics organization MAPS PBC
- 05/12/22
- Aurora Cannabis options imply 13.6% move in share price post-earnings
- 05/10/22
- Unusually active option classes on open May 10th
- 03/28/22
- Unusually active option classes on open March 28th
- 03/25/22
- Unusually active option classes on open March 25th
|
Options
|
Pre-earnings options… Pre-earnings options volume in Aurora Cannabis is 2.3x normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 13.6%, or 32c, after results are released. Median move over the past eight quarters is 10.2%. ShowHide Related Items >><< - 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 02/10/22
- Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023
- 02/03/22
- Aurora Cannabis' Reliva launches new product line, KG7
- 12/14/21
- Aurora Cannabis and 22nd Century sign license agreement with Cronos Group
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 02/11/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
- 02/03/22 CIBC
- Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
- 11/11/21 Canaccord
- Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 11/15/21
- Republicans introduce cannabis legalization bill, Insider says
- 05/12/22
- Rising High: Exclusive talk with cannabis REIT NewLake Capital
- 05/05/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 04/28/22
- Here's What You Missed in Cannabis This Week
- 04/21/22
- Rising High: Exclusive talk with psychedelics organization MAPS PBC
- 05/10/22
- Unusually active option classes on open May 10th
- 03/28/22
- Unusually active option classes on open March 28th
- 03/25/22
- Unusually active option classes on open March 25th
- 03/23/22
- Unusually active option classes on open March 23rd
|
On The Fly
| ShowHide Related Items >><< - 05/11/22
- Zynerba presents long-term safety, efficacy data of Zygel
- 05/02/22
- Zynerba presents long-term safety, efficacy data of Zygel
- 04/18/22
- Tela Bio appoints D. Taylor Ocasio as general counsel
- 02/28/22
- Zynerba announces EC grants orphan drug designation for Zygel
- 05/12/22
- Tilray announces expansion of Good Supply's cannabis portfolio
- 04/12/22
- HEXO, Tilray enter agreement for strategic alliance
- 04/12/22
- Tilray enters agreement with HEXO related to Senior Secured Convertible Note
- 04/06/22
- Tilray subsidiary Manitoba Harvest partners with Whole Foods Market
- 03/22/22
- Tilt appoints Lynn Ricci as VP, investor relations, corporate communications
- 12/28/21
- Trulieve appoints Steve White as president, Nicole Stanton as general counsel
- 12/28/21
- Trulieve Cannabis acquires PurpleMed Healting Center in Arizona
- 11/29/21
- Trulieve Cannabis issues first inaugural ESG report
RLMD Relmada Therapeutics - 04/29/22
- Relmada Therapeutics announces publication of REL-1017 preclinical study
- 02/23/22
- Relmada Therapeutics announces results from REL-1017 HAP study
- 12/22/21
- Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP
NLCP NewLake Capital Partners - 05/09/22
- NewLake Capital Partners enters revolving credit facility
- 04/06/22
- NewLake Capital Partners acquires cultivation property in Missouri for $34M
- 12/21/21
- NewLake Capital Partners acquires Missouri property for $21.1M investment
- 12/16/21
- NewLake Capital Partners raises quarterly dividend 29% to 31c per share
IGC India Globalization Capital - 12/08/21
- India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight'
- 12/02/21
- India Globalization Capital presents findings from Phase 1 trial of IGC-AD1
GTBIF Green Thumb Industries - 05/02/22
- Green Thumb announces internet availability of proxy materials for 2022 meeting
- 04/11/22
- Green Thumb Industries to open RISE Mankato on April 14
- 03/11/22
- Green Thumb Industries announces departure of Moore from board of directors
- 02/08/22
- Green Thumb Industries appoints Dorri McWhorter to board of directors
- 02/28/22
- Goodness Growth launches full line of cannabis flower in Minnesota
- 02/01/22
- Verano Holdings to acquire Goodness Growth in $413M all-share transaction
- 03/08/22
- CV Sciences adds +PlusCBD Relief Softgels to its Wellness line
- 01/11/22
- CV Sciences launches +PlusCBD Pain Relief topicals
- 01/05/22
- CV Sciences announces new distribution agreement with GNC
- 11/15/21
- CV Sciences announces convertible note financing
- 01/06/22
- CannTrust reports implementation of CCAA plan, settlement of lawsuits
- 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/09/22
- Compass Pathways to fund study of COMP360 psilocybin in autistic adults
- 05/03/22
- Compass Pathways announces data on COMP360 psilocybin therapy
- 04/20/22
- Compass Pathways partners with One Mind for Rising Star Awards
- 03/24/22
- Compass Pathways, partners to launch psychedelic research facility
- 04/26/22
- Canopy Growth expects to generate savings of $100M-$150M within 12-18 months
- 04/26/22
- Canopy Growth announces cost reduction initiatives including headcount reduction
- 03/31/22
- Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO
- 03/22/22
- Canopy Growth announces results from trial using CBD on menstrual symptoms
- 03/30/22
- Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago
- 02/01/22
- IntelGenx receives third loan tranche from Atai Life Sciences
- 01/27/22
- Atai Life Sciences to partner with Dalriada
- 01/12/22
- atai Life Sciences' IND for PCN-101 approved by FDA
- 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 02/10/22
- Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023
- 02/03/22
- Aurora Cannabis' Reliva launches new product line, KG7
- 12/14/21
- Aurora Cannabis and 22nd Century sign license agreement with Cronos Group
RLMD Relmada Therapeutics - 05/09/22 Oppenheimer
- Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
- 12/20/21 SVB Leerink
- Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
- 11/17/21 Mizuho
- Relmada Therapeutics initiated with a Buy at Mizuho
- 09/30/21 Jefferies
- Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
- 02/28/22 Canaccord
- Compass Pathways price target lowered to $78 from $80 at Canaccord
- 11/11/21 Roth Capital
- Atai Life Sciences initiated with a Buy at Roth Capital
- 11/09/21 Citi
- Citi says Compass Pathways selloff overdone, ups price target to $70
- 11/09/21 Cantor Fitzgerald
- Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
- 04/01/22 Canaccord
- Atai Life Sciences price target lowered to $27 from $28 at Canaccord
- 03/31/22 RBC Capital
- Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
- 11/30/21
- Fly Intel: Top five analyst initiations
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 06/25/21 Alliance Global Partners
- Cannabis selloff brings buying opportunities, says Alliance Global
- 05/12/22 Alliance Global Partners
- Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
- 03/31/22 Canaccord
- Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
- 03/30/22 Alliance Global Partners
- Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
- 05/02/22 Alliance Global Partners
- Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
- 04/20/22 Barclays
- Tilray price target lowered to $4.50 from $8.50 at Barclays
- 04/06/22 MKM Partners
- Tilray margins contracted despite cost savings, says MKM Partners
- 04/06/22 Benchmark
- Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital GTBIF Green Thumb Industries - 05/05/22 Alliance Global Partners
- Green Thumb price target lowered to C$38 from C$40 at Alliance Global
- 05/05/22 Craig-Hallum
- Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
- 05/05/22 Needham
- Green Thumb Industries price target lowered to $26 from $33 at Needham
- 05/12/22 Canaccord
- Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
- 02/01/22 Craig-Hallum
- Goodness Growth downgraded to Hold from Buy at Craig-Hallum
- 11/11/21 Canaccord
- Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
- 05/11/22 CIBC
- CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
- 05/11/22 Canaccord
- Cronos upgraded to Hold on operational improvements at Canaccord
- 05/11/22 CIBC
- Cronos Group upgraded to Outperformer from Neutral at CIBC
- 05/11/22 Canaccord
- Cronos Group upgraded to Hold from Sell at Canaccord
- 04/04/22 Morgan Stanley
- Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
- 03/22/22 Barclays
- Canopy Growth downgraded to Underweight from Equal Weight at Barclays
- 03/01/22 Barclays
- Canopy Growth price target lowered to $9 from $14 at Barclays
- 05/13/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
- 02/11/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
- 02/03/22 CIBC
- Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
NLCP NewLake Capital Partners - 03/21/22 Ladenburg
- NewLake Capital price target lowered to $39.50 from $44 at Ladenburg
- 09/08/21 Compass Point
- NewLake Capital Partners initiated with a Buy at Compass Point
- 09/07/21 Ladenburg
- NewLake Capital Partners initiated with a Buy at Ladenburg
- 03/01/22
- Zynerba reports Q4 EPS (22c), consensus (26c)
- 11/15/21
- Zynerba reports Q3 EPS (26c), consensus (25c)
- 04/06/22
- Tilray reports Q3 EPS 9c vs. ($1.03) last year
- 01/10/22
- Tilray reports Q2 revenue $155M vs. $129M last year
- 05/12/22
- Trulieve Cannabis reiterates 2022 revenue view $1.3B-$1.4B
- 05/12/22
- Trulieve Cannabis reports Q1 adjusted EPS 1c vs. 30c last year
RLMD Relmada Therapeutics - 05/05/22
- Relmada Therapeutics reports Q1 EPS ($1.40), consensus ($1.27)
- 03/23/22
- Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83)
NLCP NewLake Capital Partners - 03/17/22
- NewLake Capital Partners reports Q4 adjusted FFO 32c vs. 63c last year
GTBIF Green Thumb Industries - 03/01/22
- Green Thumb Industries reports Q4 EPS 10c vs. 11c last year
- 11/15/21
- CV Sciences reports Q3 EPS 0c vs. (3c) last year
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 05/10/22
- Compass Pathways reports Q1 EPS (50c), consensus (67c)
- 02/24/22
- Compass Pathways reports Q4 EPS (61c), consensus (50c)
- 04/07/22
- Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55
- 02/09/22
- Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago
- 11/15/21
- Atai Life Sciences reports Q3 EPS (21c), consensus (20c)
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
|
Options
|
Unusual total active… Unusual total active option classes on open include: Vertex Energy (VTNR), Aurora Cannabis (ACB), Nokia (NOK), FuelCell (FCEL), ProShares UltraShort Lehman 20 plus Year Treasury (TBT), Rivian (RIVN), Li Auto (LI), Technology Sector SPDR ETF (XLK), Altria Group (MO), and iShares Emerging Markets Bond ETF (EMB). ShowHide Related Items >><< - 04/01/22
- Vertex Energy completes acquisition of Mobile refinery from Shell
- 02/17/22
- Vertex Energy announces five-year renewable diesel supply agreement
- 05/08/22
- Fly Intel: Top five weekend stock stories
- 05/03/22
- Rivian to receive $1.5B incentives package to build EV factory in Georgia
- 04/28/22
- Rivian Automotive, Clearloop partner on renewable electricity
- 04/14/22
- Rivian Automotive appoints Anisa Kamadoli Costa as chief sustainability officer
- 05/09/22
- Nokia launches cybersecurity-focused testing lab in US
- 05/06/22
- Nokia chief people officer Stephanie Werner-Dietz to step down
- 04/12/22
- Nokia to exit Russian market, sees EUR 100M provision in Q1
- 03/29/22
- Nokia selected by Chunghwa Telecom to enhance 5G network across Taiwan
- 04/28/22
- FDA proposes rules prohibiting menthol cigarettes and flavored cigars
- 04/13/22
- JUUL to pay Washington $22.5M over advertising practices
- 04/11/22
- Lexaria Bioscience enters new agreements with Altria Client Services
- 03/11/22
- FDA authorizes reduced exposure claim for IQOS 3 System Holder and Charger
- 05/01/22
- Li Auto delivers 4,167 Li ONEs in April 2022
- 04/22/22
- Li Auto updates status under HFCAA
- 04/21/22
- Li Auto, KE Holdings among new additions to SEC HFCAA provisional list
- 04/01/22
- Li Auto delivers 11,034 Li Ones in March and 31,716 in Q1
- 05/05/22
- FuelCell extends term of agreement with ExxonMobil
- 04/06/22
- FuelCell appoints Feasel as EVP, CCO
- 02/17/22
- FuelCell says carbon capture demonstration project awarded $6.8M by CRIN
- 02/02/22
- FuelCell releases first sustainability report
- 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 02/10/22
- Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023
- 02/03/22
- Aurora Cannabis' Reliva launches new product line, KG7
- 12/14/21
- Aurora Cannabis and 22nd Century sign license agreement with Cronos Group
- 12/01/21 Credit Suisse
- Vertex Energy initiated with an Outperform at Credit Suisse
- 11/09/21 Craig-Hallum
- Vertex Energy price target lowered to $18 from $25 at Craig-Hallum
- 06/30/21 Craig-Hallum
- Vertex Energy price target raised to $25 from $13 at Craig-Hallum
- 06/01/21 Stifel
- Vertex Energy price target raised to $17 from $2 at Stifel
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 02/11/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
- 02/03/22 CIBC
- Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
- 11/11/21 Canaccord
- Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
- 04/29/22 UBS
- Nokia price target lowered to EUR 5.80 from EUR 6.20 at UBS
- 04/29/22 Societe Generale
- Nokia price target lowered to EUR 6.10 from EUR 6.70 at Societe Generale
- 03/17/22 Jefferies
- Nokia initiated with a Buy at Jefferies
- 03/14/22 Raymond James
- Raymond James upgrades Nokia to Outperform on improved position
- 04/26/22 KeyBanc
- KeyBanc says Axios report positive for Plug Power, other fuel cell names
- 02/08/22 B. Riley
- FuelCell price target lowered to $5 from $6 at B. Riley
- 01/20/22 JPMorgan
- FuelCell price target lowered to $5 from $7 at JPMorgan
- 01/05/22 KeyBanc
- FuelCell initiated with a Sector Weight at KeyBanc
TBT ProShares UltraShort 20+ yr Trsry - 05/02/22 Piper Sandler
- Piper Sandler favors Rivian for exposure to commercial vans
- 05/02/22 Benchmark
- Ford price target lowered to $25 from $29 at Benchmark
- 04/26/22 Barclays
- Rivian Automotive price target lowered to $38 from $42 at Barclays
- 04/25/22 JPMorgan
- Ford price target lowered to $21 from $22 at JPMorgan
- 04/04/22 UBS
- Li Auto price target raised to $52 from $47 at UBS
- 04/01/22 HSBC
- Li Auto initiated with a Buy at HSBC
- 03/24/22 China Renaissance
- China Renaissance starts 'bellwether' Li Auto with Buy, $37.20 target
- 03/23/22 China Renaissance
- Li Auto initiated with a Buy at China Renaissance
XLK Technology Select Sector SPDR - 05/10/22 Bernstein
- Altria Group downgraded to Market Perform from Outperform at Bernstein
- 05/09/22 Jefferies
- PM buying Swedish Match would have negative read for Altria, says Jefferies
- 04/29/22 Deutsche Bank
- Altria Group price target raised to $60 from $54 at Deutsche Bank
- 04/07/22 Cowen
- Altria Group price target raised to $53 from $51 at Cowen
EMB iShares JP Morgan USD Emerging Markets Bond ETF - 05/10/22
- Vertex Energy sees FY23 adjusted EBITDA $425M-$450M
- 05/10/22
- Vertex Energy sees FY22 adjusted EBITDA $340M-$360M
- 05/10/22
- Vertex Energy reports Q1 EPS (8c), consensus (14c)
- 03/08/22
- Vertex Energy reports 2021 EPS (36c), consensus (21c)
- 04/28/22
- Amazon reports Q1 EPS ($7.56) with Rivian expense, consensus $8.36
- 03/10/22
- Rivian sees FY22 adjusted EBITDA ($4.75B)
- 03/10/22
- Rivian reports Q4 EPS ($4.83) vs ($1.97)
- 03/10/22
- Notable companies reporting after market close
- 04/28/22
- Nokia raises FY22 revenue view to EUR 22.9B-EUR 24.1B from EUR 22.6B-EUR 23.8B
- 04/28/22
- Nokia reports Q1 comparable EPS EUR 0.07 vs EUR 0.07 last year
- 02/03/22
- Nokia sees FY22 revenue EUR 22.6B-EUR 23.8B
- 02/03/22
- Nokia reports Q4 comparable EPS EUR0.13 vs. EUR 0.14 last year
- 04/28/22
- Altria Group backs FY22 adjusted EPS $4.79-$4.93, consensus $4.84
- 04/28/22
- Altria Group reports Q1 adjusted EPS $1.12, consensus $1.18
- 04/27/22
- Notable companies reporting before tomorrow's open
- 02/25/22
- Li Auto sees Q1 revenue $1.39B-$1.48B, one estimate $1.58B
- 02/25/22
- Li Auto reports Q4 EPS 2c, consensus (4c)
- 02/24/22
- Notable companies reporting before tomorrow's open
- 03/10/22
- FuelCell reports Q4 EPS (11c), consensus (5c)
- 12/29/21
- FuelCell reports Q4 EPS (7c), consensus (4c)
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
|
On The Fly
| ShowHide Related Items >><< - 05/02/22
- Zynerba presents long-term safety, efficacy data of Zygel
- 04/18/22
- Tela Bio appoints D. Taylor Ocasio as general counsel
- 02/28/22
- Zynerba announces EC grants orphan drug designation for Zygel
- 02/28/22
- Zynerba announces completion of enrollment in Phase 2 trial of Zygel
- 05/05/22
- Wesana Health to conduct strategic review of care delivery division
- 03/22/22
- Wesana Health announces data from animal study of psilocybin
- 03/14/22
- Wesana Health announces feedback from pre-IND meeting on SANA-013
- 02/02/22
- Jones Soda, Wesana Health, Mike Tyson partner to launch nootropic supplement
- 04/12/22
- HEXO, Tilray enter agreement for strategic alliance
- 04/12/22
- Tilray enters agreement with HEXO related to Senior Secured Convertible Note
- 04/06/22
- Tilray subsidiary Manitoba Harvest partners with Whole Foods Market
- 04/05/22
- Tilray announces Solei brand launches cannabis edible in Quebec
- 03/22/22
- Tilt appoints Lynn Ricci as VP, investor relations, corporate communications
- 12/28/21
- Trulieve appoints Steve White as president, Nicole Stanton as general counsel
- 12/28/21
- Trulieve Cannabis acquires PurpleMed Healting Center in Arizona
- 11/29/21
- Trulieve Cannabis issues first inaugural ESG report
RLMD Relmada Therapeutics - 04/29/22
- Relmada Therapeutics announces publication of REL-1017 preclinical study
- 02/23/22
- Relmada Therapeutics announces results from REL-1017 HAP study
- 12/22/21
- Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP
IGC India Globalization Capital - 12/08/21
- India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight'
- 12/02/21
- India Globalization Capital presents findings from Phase 1 trial of IGC-AD1
GTBIF Green Thumb Industries - 05/02/22
- Green Thumb announces internet availability of proxy materials for 2022 meeting
- 04/11/22
- Green Thumb Industries to open RISE Mankato on April 14
- 03/11/22
- Green Thumb Industries announces departure of Moore from board of directors
- 02/08/22
- Green Thumb Industries appoints Dorri McWhorter to board of directors
- 02/28/22
- Goodness Growth launches full line of cannabis flower in Minnesota
- 02/01/22
- Verano Holdings to acquire Goodness Growth in $413M all-share transaction
- 05/04/22
- Entourage Health partners with Pineapple Express for same-day cannabis delivery
- 05/03/22
- Entourage Health reaffirms preliminary 2021 revenue C$55.2M
- 03/25/22
- Entourage Health launches 'Joints for Justice' retail campaign
- 03/24/22
- Entourage Health updates timing for Q4, 2021 financials
- 03/08/22
- CV Sciences adds +PlusCBD Relief Softgels to its Wellness line
- 01/11/22
- CV Sciences launches +PlusCBD Pain Relief topicals
- 01/05/22
- CV Sciences announces new distribution agreement with GNC
- 11/15/21
- CV Sciences announces convertible note financing
- 01/06/22
- CannTrust reports implementation of CCAA plan, settlement of lawsuits
- 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/03/22
- Compass Pathways announces data on COMP360 psilocybin therapy
- 04/20/22
- Compass Pathways partners with One Mind for Rising Star Awards
- 03/24/22
- Compass Pathways, partners to launch psychedelic research facility
- 01/19/22
- Compass Pathways announces results from survey conducted with Sermo on TRD
- 04/26/22
- Canopy Growth expects to generate savings of $100M-$150M within 12-18 months
- 04/26/22
- Canopy Growth announces cost reduction initiatives including headcount reduction
- 03/31/22
- Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO
- 03/22/22
- Canopy Growth announces results from trial using CBD on menstrual symptoms
- 03/30/22
- Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago
- 02/01/22
- IntelGenx receives third loan tranche from Atai Life Sciences
- 01/27/22
- Atai Life Sciences to partner with Dalriada
- 01/12/22
- atai Life Sciences' IND for PCN-101 approved by FDA
- 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 02/10/22
- Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023
- 02/03/22
- Aurora Cannabis' Reliva launches new product line, KG7
- 12/14/21
- Aurora Cannabis and 22nd Century sign license agreement with Cronos Group
GTBIF Green Thumb Industries - 05/05/22 Alliance Global Partners
- Green Thumb price target lowered to C$38 from C$40 at Alliance Global
- 05/05/22 Craig-Hallum
- Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
- 05/05/22 Needham
- Green Thumb Industries price target lowered to $26 from $33 at Needham
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 11/18/21 Canaccord
- Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
- 11/17/21 Canaccord
- Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
FFLWF Fire & Flower Holdings - 04/28/22 Stifel
- Fire & Flower Holdings price target lowered to C$8.50 from C$12 at Stifel
- 12/15/21 Stifel
- Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel
- 11/23/21 Cantor Fitzgerald
- Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald
- 11/22/21 Cantor Fitzgerald
- Fire & Flower initiated with an Overweight at Cantor Fitzgerald
- 02/28/22 Canaccord
- Compass Pathways price target lowered to $78 from $80 at Canaccord
- 11/11/21 Roth Capital
- Atai Life Sciences initiated with a Buy at Roth Capital
- 11/09/21 Citi
- Citi says Compass Pathways selloff overdone, ups price target to $70
- 11/09/21 Cantor Fitzgerald
- Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
- 04/01/22 Stifel
- Wesana Health initiated with a Speculative Buy at Stifel
- 05/02/22 Alliance Global Partners
- Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
- 04/20/22 Barclays
- Tilray price target lowered to $4.50 from $8.50 at Barclays
- 04/06/22 MKM Partners
- Tilray margins contracted despite cost savings, says MKM Partners
- 04/06/22 Benchmark
- Tilray fiscal Q3 results 'disappointing,' says Benchmark
- 02/11/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
- 02/03/22 CIBC
- Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
- 11/11/21 Canaccord
- Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
- 06/25/21 Alliance Global Partners
- Cannabis selloff brings buying opportunities, says Alliance Global
- 04/04/22 Morgan Stanley
- Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
- 03/22/22 Barclays
- Canopy Growth downgraded to Underweight from Equal Weight at Barclays
- 03/01/22 Barclays
- Canopy Growth price target lowered to $9 from $14 at Barclays
- 03/22/22 Barclays
- Cronos Group upgraded to Equal Weight from Underweight at Barclays
- 03/21/22 Stifel
- Stifel takes neutral overall view of Cronos' CEO transition
- 03/07/22 Piper Sandler
- Cronos Group price target lowered to $3 from $4 at Piper Sandler
- 02/01/22 Craig-Hallum
- Goodness Growth downgraded to Hold from Buy at Craig-Hallum
- 11/11/21 Canaccord
- Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
IGC India Globalization Capital - 03/31/22 Canaccord
- Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
- 03/30/22 Alliance Global Partners
- Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
- 03/29/22 Cantor Fitzgerald
- Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald
- 05/06/21 Cantor Fitzgerald
- Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
RLMD Relmada Therapeutics - 12/20/21 SVB Leerink
- Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
- 11/17/21 Mizuho
- Relmada Therapeutics initiated with a Buy at Mizuho
- 09/30/21 Jefferies
- Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
- 07/28/21 Truist
- Relmada Therapeutics price target raised to $90 from $75 at Truist
- 04/01/22 Canaccord
- Atai Life Sciences price target lowered to $27 from $28 at Canaccord
- 03/31/22 RBC Capital
- Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
- 11/30/21
- Fly Intel: Top five analyst initiations
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 03/01/22
- Zynerba reports Q4 EPS (22c), consensus (26c)
- 11/15/21
- Zynerba reports Q3 EPS (26c), consensus (25c)
- 04/06/22
- Tilray reports Q3 EPS 9c vs. ($1.03) last year
- 01/10/22
- Tilray reports Q2 revenue $155M vs. $129M last year
RLMD Relmada Therapeutics - 03/23/22
- Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83)
- 11/11/21
- Relmada Therapeutics reports Q3 EPS ($2.44), consensus ($1.60)
GTBIF Green Thumb Industries - 03/01/22
- Green Thumb Industries reports Q4 EPS 10c vs. 11c last year
- 04/22/22
- Entourage Health reaffirms preliminary 2021 revenue C$54.8M
- 02/11/22
- Entourage Health reports 2021 revenue C$54.8M, up 54% y-o-y
- 11/16/21
- Entourage Health reports Q3 revenue C$14.9M vs. C$7.74M last year
- 11/15/21
- CV Sciences reports Q3 EPS 0c vs. (3c) last year
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 02/24/22
- Compass Pathways reports Q4 EPS (61c), consensus (50c)
- 11/09/21
- Compass Pathways reports Q3 EPS (38c), consensus (49c)
- 04/07/22
- Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55
- 02/09/22
- Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago
- 11/15/21
- Atai Life Sciences reports Q3 EPS (21c), consensus (20c)
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
- 11/09/21
- Aurora Cannabis reports Q1 revenue C$60.1M vs. C$67.59M last year
|